Addressing partial response, or non-response, to schizophrenia treatment

Lack of adequate response to pharmacological treatment of schizophrenia is relatively common. Among individuals with recent-onset schizophrenia, non-response rates may be as high as 20% of cases. Among those with chronic illness, non-response to pharmacotherapy may occur in up to half of individuals, according to some estimates.

This is the PowerPoint deck from a presentation to the First Episode Schizophrenia Treatment group on 26 July, 2017. The topic was: Addressing partial-response or non-response in the treatment of schizophrenia.

Topics include:

  • General approach to treatment non-response
  • The possibility that “treatment-resistant schizophrenia” is a physiologically distinct form of illness, and that this separate pathophysiology may explain non-response to first-line pharmacotherapies.
  • Review of efficacy of clozapine in this form of illness
  • Non-dopaminergic treatment strategies

Addressing partial response, or non-response, to schizophrenia treatment